Impact Biomedical (IBO) EBT (2022 - 2026)

Impact Biomedical (IBO) has reported EBT for 5 consecutive years, with -$700000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 95.12% year-over-year to -$700000.0; the trailing twelve-month figure through Jun 2026 stood at -$18.8 million (up 51.13% YoY), and the FY2024 full-year result was -$24.7 million, down 461.31% from the prior year.
• EBT advanced to -$700000.0 in Q2 2026 per IBO's latest filing, from -$2.3 million in the prior quarter.
• Across five years, EBT topped out at $4.2 million in Q3 2024 and bottomed at -$27.1 million in Q4 2024.
• Historically, EBT has averaged -$3.5 million across 5 years, with a median of -$1.1 million in 2023.
• The widest YoY moves for EBT: up 460.32% in 2024, down 2049.09% in 2024.
• Over 5 years, EBT stood at -$5.2 million in 2022, then jumped by 75.96% to -$1.3 million in 2023, then tumbled by 2049.09% to -$27.1 million in 2024, then surged by 94.56% to -$1.5 million in 2025, then surged by 52.54% to -$700000.0 in 2026.
• According to Business Quant data, EBT over the past three periods registered -$700000.0, -$2.3 million, and -$1.5 million for Q2 2026, Q1 2026, and Q3 2025 respectively.